Physician partner Director of Clinical Research
Oncology
Dr. Peter I. Acs, MD
|
|
Give Review
Peter I. Acs, MD practices Oncology. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Peter is also a published doctor. He has 36 paper published. The most recent paper is: Protein kinase C delta (PKCdelta) inhibits the expression of glutamine synthetase in glial cells via the PKCdelta regulatory domain and its tyrosine phosphorylation. He is registered with Medicare.
Publications
- The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor-Positive Early Stage Breast Cancer and Correlation with Est...
- [Protein kinase C as a potential target for drug development in cancer research].
- Prominent stress response of Purkinje cells in Creutzfeldt-Jakob disease.
- Differential activation and desensitization of sensory neurons by resiniferatoxin.
- The stimulation of capsaicin-sensitive neurones in a vanilloid receptor-mediated fashion by pungent terpenoids possessing an unsaturated 1,4-dialdehyde moiety.
- Characterization of functional vanilloid receptors expressed by mast cells.
- Specific vanilloid responses in C6 rat glioma cells.
- Recent advances in understanding of vanilloid receptors: a therapeutic target for treatment of pain and inflammation in skin.
- Protein kinase C-epsilon plays a role in neurite outgrowth in response to epidermal growth factor and nerve growth factor in PC12 cells.
- The catalytic domain of PKC-epsilon, in reciprocal PKC-delta and -epsilon chimeras, is responsible for conferring tumorgenicity to NIH3T3 cells, whereas both regulator...
- Non-equivalent roles for the first and second zinc fingers of protein kinase Cdelta. Effect of their mutation on phorbol ester-induced translocation in NIH 3T3 cells.
- Effect of a tyrosine 155 to phenylalanine mutation of protein kinase cdelta on the proliferative and tumorigenic properties of NIH 3T3 fibroblasts.
- Differential role of specific PKC isoforms in the proliferation of glial cells and the expression of the astrocytic markers GFAP and glutamine synthetase.
- Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-bi...
- Regulation of actin cytoskeleton in lymphocytes: PKC-delta disrupts IL-3-induced membrane ruffles downstream of Rac1.
- Opposite roles of protein kinase C isoforms in proliferation, differentiation, apoptosis, and tumorigenicity of human HaCaT keratinocytes.
- The catalytic domain of protein kinase C-delta in reciprocal delta and epsilon chimeras mediates phorbol ester-induced macrophage differentiation of mouse promyelocytes.
- The catalytic domain of protein kinase C chimeras modulates the affinity and targeting of phorbol ester-induced translocation.
- Differential activation of PKC isozymes by 14-3-3 zeta protein.
- Both the catalytic and regulatory domains of protein kinase C chimeras modulate the proliferative properties of NIH 3T3 cells.
- Functional effects of overexpression of protein kinase C-alpha, -beta, -delta, -epsilon, and -eta in the mast cell line RBL-2H3.
- Comparison of the roles of the C1a and C1b domains of protein kinase C alpha in ligand induced translocation in NIH 3T3 cells.
- Protein kinase C delta (PKCdelta) inhibits the expression of glutamine synthetase in glial cells via the PKCdelta regulatory domain and its tyrosine phosphorylation.
- The catalytic domain of protein kinase Cdelta confers protection from down-regulation induced by bryostatin 1.
- Differential selectivity of ligands for the C1a and C1b phorbol ester binding domains of protein kinase Cdelta: possible correlation with tumor-promoting activity.
- Protein kinase C in cell signaling: strategies for the development of selective inhibitors.
- Conformationally constrained analogues of diacylglycerol. 13. Protein kinase C ligands based on templates derived from 2,3-dideoxy-L-erythro(threo)-hexono-1,4-lactone ...
- Erythropoietin and erythropoietin receptor expression in human cancer.
- Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death.
- 17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice.
- Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells.
- Prognostic significance of erythropoietin expression in human endometrial carcinoma.
- Conformationally constrained diacylglycerol (DAG) analogs: 4-C-hydroxyethyl-5-O-acyl-2,3-dideoxy-D-glyceropentono-1,4-lactone analogs as protein kinase C (PKC) ligands.
- Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis an...
- Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma.
Schools
Debrecen Medical University
Huron Hospital
Georgetown University
Procedures Preformed
- CT Scan (Computed Tomography)
- PET Scan
Doctors Specialties
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Georgetown University Hospital -
University of Debrecen Medical and Health Science Center
Drug Facts
| NPI NUMBER | 1861445421 | |
| NPPES Provider LastName | ACS | |
| NPPES Provider FirstName | PETER | |
| NPPES Provider ZIPCode | 326054218 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1812.0 | |
| Distinct Opioid Count | 9.0 | |
| Opioid Claim Count | 333.0 | |
| Percent Opioid Claims | 18.38 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1861445421 |
| Last Name Of The Provider | ACS |
| First Name Of The Provider | PETER |
| View All |
Similar Doctors
|
Dr. David N. Reisman, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. John R. Wingard, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Stephen P. Staal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carmen J. Allegra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Coy D. Heldermon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Merry J. Markham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel J. Farrugia, MD
This Doctor is OpenDoctor Recommended.
|